

10/506383

DT09 Rec'd PCT/PTO 02 SEP 2004

PATENT

ATTORNEY DOCKET NUMBER: 50125/095001

Certificate of Mailing


Date of Deposit: September 2, 2004

Label Number: EV293693801US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elvis De La Cruz

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jörg Stürzebecher et al. Art Unit:

Serial No.: Not yet assigned Examiner:

Filed: September 2, 2004 Customer No.: 21559

Title: INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa,
PRODUCTION THEREOF AND USE OF THE SAME

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed with the application.

10/506383


DT09 Rec'd PCT/PTO 02 SEP 2004

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 2 September 2004



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

F:\50125\50125.095001 Information Disclosure Statement filed with app.doc

SUBSTITUTE FORM PTO-1449 (MODIFIED)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			Attorney Docket No. 50125/095001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						Serial No. Not yet assigned	
						Applicant Jörg Stürzebecher et al.	
						Filing Date September 2, 2004	
						Group Not yet assigned	
						IDS Filed September 2, 2004	
(37 C.F.R. § 1.98(b))							
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)	
	6,030,972	02/29/00	Bohm et al.				
	5,726,159	03/10/98	Schacht et al.				
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
	WO 01/96366 A2	12/20/01	PCT				
	WO 00/58346	10/05/00	PCT				
	WO 94/29336	12/22/94	PCT				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Dixon, "The Determination of Enzyme Inhibitor Constants," <i>Biochem. J.</i> 55:170-171 (1953).						
	Frérot et al., "PyBOP® and PyBroP: Two Reagents for the Difficult Coupling of the α , α -Dialkyl Amino Acid, Aib," <i>Tetrahedron</i> 47:259-270 (1991).						
	Hara et al., "DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa," <i>Thrombosis and Haemostasis</i> 71:314-319 (1994).						
	Herbert et al., "DX 9065A, a Novel, Synthetic, Selective and Orally Active Inhibitor of Factor Xa: <i>In Vitro</i> and <i>In Vivo</i> Studies," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 276:1030-1038 (1996).						
	Ho et al., "Exploratory Solid-Phase Synthesis of Factor Xa Inhibitors: Discovery and Application of P ₃ -Heterocyclic Amides as Novel Types of Non-Basic Arginine Surrogates," <i>Bioorganic & Medicinal Chemistry Letters</i> 9:3459-3464 (1999).						
	Kettner et al., "The Selective Affinity Labeling of Factor Xa by Peptides of Arginine Chloromethyl Ketone," <i>Thrombosis Research</i> 22:645-652 (1981).						
	Kim et al., "Preparation of Argatroban Analog Thrombin Inhibitors with Reduced Basic Guanidine Moiety, and Studies of Their Cell Permeability and Antithrombotic Activities," <i>Med. Chem. Res.</i> 377-383 (1996).						
	Kirk, "4-Lithio-1-Tritylimidazole as a Synthetic Intermediate, Synthesis of Imidazole-4-Carboxaldehyde," <i>J. Heterocyclic Chem</i> 22:57-59 (1985).						
	Künzel et al., "4-Amidinobenzylamine-Based Inhibitors of Urokinase," <i>Bioorganic & Medicinal Chemistry Letters</i> 12:645-648 (2002).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50125/026001 Serial No. 10/506383 Not yet assigned Applicant Jörg Stürzebecher et al. Filing Date September 2, 2004 Group Not yet assigned IDS Filed September 2, 2004	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					
(37 C.F.R. § 1.98(b))					
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
Lee et al., "Noncovalent Thrombin Inhibitors Incorporating an Imidazolethynyl P1," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:2775-2778 (2000).					
Maduskuie et al., "Rational Design and Synthesis of Novel, Potent Bis-Phenylamidine Carboxylate Factor Xa Inhibitors," <i>J. Med. Chem.</i> 41:53-62 (1998).					
Mohan et al., "Solid-Phase Synthesis of N-Substituted Amidinophenoxy Pyridines as Factor Xa Inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> 8:1877-1882 (1998).					
Phillips et al., "Discovery of N-[2-[5-[Amino (imino)Methyl]-2-Hydroxyphenoxy]-3,5-Difluoro-6-[3-(4,5-Dihydro-1-Methyl-1 H-Imidazol-2-yl) Phenoxy] Pyridin-4-yl]-N-methylglycine (ZK-807834): A Potent, Selective, and Orally Active Inhibitor of the Blood Coagulation Enzyme Factor Xa ¹ ," <i>J. Med. Chem.</i> 41:3557-3562 (1998).					
Ostrem et al., "Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors Via Combinatorial Chemistry," <i>Biochemistry</i> 37:1053-1059 (1998).					
Quan et al., "Bisbenzamidine Isoxazoline Derivatives as Factor Xa Inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> 7:2813-2818 (1997).					
Sato et al., "Antithrombotic Effects of YM-60828, a Newly Synthesized Factor Xa Inhibitor, in Rat Thrombosis Models and its Effects on Bleeding Time," <i>British Journal of Pharmacology</i> 123:92-96 (1998).					
Sato et al., "YM-60828, a Novel Factor Xa Inhibitor: Separation of its Antithrombotic Effects From its Prolongation of Bleeding Time," <i>European Journal of Pharmacology</i> 339:141-146 (1997).					
Schechter et al., "On the Size of the Active Site in Proteases," <i>Biochemical and Biophysical Research Communications</i> , 27:157-162 (1967).					
Soll et al., "Amidinohydrazones as Guanidine Bioisosteres: Application to a New Class of Potent, Selective and Orally Bioavailable, Non-Amide-Based Small Molecule Thrombin Inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> 10:1-4 (2000).					
Sperl et al., "Urethanyl-3-Amidinophenylalanine Derivatives as Inhibitors of Factor Xa. X-Ray Crystal Structure of a Trypsin/Inhibitor Complex and Modeling Studies," <i>Biol. Chem.</i> 381:321-329 (2000).					
Stürzebecher et al., "Synthetic Inhibitors of Bovine Factor Xa and Thrombin Comparison of Their Anticoagulant Efficiency," <i>Thrombosis Research</i> 54:245-252 (1989).					
Sucker et al., "Pharm. Techn. 2.," Bauer, Georg Thieme Verlag, Stuttgart, 1991.					
Von der Saal et al., "Derivatives of 4-Amino-Pyridine as Selective Thrombin Inhibitors," <i>Bioorganic & Medicinal Chemistry Letters</i> 7:1283-1288 (1997).					
Zhu et al., "Recent Advances in Inhibitors of Factor Xa in the Prothrombinase Complex," <i>Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs</i> 1:63-88 (1999).					
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					